Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.

Ionis Pharmaceuticals

Cystic Fibrosis Foundation

Sozo Ventures

Agent Capital

RA Capital Management

Leaps by Bayer

HOF Capital

Humboldt Fund

InCube Ventures

Yaya Capital

Surveyor Capital

Novo Holdings

Marshall Wace

Millennium Management

Bristol Myers Squibb

Deep Track Capital

Eventide

Farallon Capital Management

Frazier Healthcare Partners

SymBiosis LLC

Catalio Capital Management

Moderna

Metagenomi

From our team to yours, we wish you a safe and joyful holiday season. As we wind down for our annual winter break, we look forward to what’s to come in the new year.

During AIChE's 6th International Conference on CRISPR Technologies, which took place October 17-19th in Boston, MA, Metagenomi gave one oral presentation and two poster presentations.  What scientific findings did we present at this conference?

Last year, we published new data in Nature Portfolio describing novel, compact RNA-guided nucleases used to develop the smallest adenine base editor (ABE) to date. This ABE, at just 623 amino acids in size, is highly active in cells.

Metagenomi’s discovery could potentially enable novel in vivo delivery options for our precision genetic medicines. To learn more about Metagenomi's discovery platform, visit our website, and see the link below to learn more about our findings. 

Read more: https://lnkd.in/gebRnH5K

Today’s historic FDA approval of the first CRISPR-based therapy is a remarkable step forward for both sickle cell patients and the field of gene editing. We wholeheartedly celebrate this major milestone and congratulate the countless scientists and researchers dedicated to creating curative genetic medicines for patients in need.

https://lnkd.in/gWdrjeun

At Metagenomi, we believe that our values are foundational to who we are as an organization. In October we internally debuted the new set of company values that are reflective of our shared vision and commitment to excellence, and will guide us on our journey ahead.

With extensive input from our employees and executive team, we've distilled our core principles into three pillars that shape our identity:

-Driven by innovation
-Dedicated to scientific rigor
-Championed by each other

At the internal unveiling event, we celebrated our corporate values through historical recount and storytelling of Metagenomi's evolution, describing key moments that have informed our distinct culture. Check a photo from the event below, and visit https://lnkd.in/gJUhW6FJ to learn more.

Metagenomi is presenting during the 4th annual CRISPR 2.0 Congress from November 28-30th in Boston, MA. On Thursday, November 30th, Metagenomi will be giving two presentations:

Alan Brooks will be presenting ‘A Novel Type V CRISPR System With Potent Editing Activity in Mice and Non-Human Primates’ at 11:45 am ET . 

Chris Brown will be giving a talk titled ‘Enabling Rapid Discovery and Development of Next-Generation Genome Editing Tools Through Metagenomics’ at 3:45 pm ET.

Happy Thanksgiving! We're thankful for the incredible team at Metagenomi who work tirelessly every day to create poten­tial­ly cura­tive ther­a­peu­tics. 

#Metagenomi #HappyThanksgiving

At Metagenomi, our ultra-small nucle­as­es are high­ly effi­cient genome edit­ing sys­tems that have the poten­tial for exten­sive ther­a­peu­tic appli­ca­tions. We have pri­or­i­tized find­ing sys­tems to over­come the size con­straints of first gen­er­a­tion nucle­as­es. Our sys­tems are a frac­tion of the size and pack­age eas­i­ly into a sin­gle AAV for tar­get­ing organs beyond what is pos­si­ble with lipid nanopar­ti­cle delivery.

Learn more about our systems: https://lnkd.in/gyxsjbYB 

#Metagenomi

Today, the UK officially authorized the very first CRISPR-based gene editing therapy for use. This is a momentous day for our field and a huge step forward in paving the way for curative genetic medicines to become standardized treatments. Of course, this is an exciting day for the field, but moreover, its an astounding win for patients and families.

https://lnkd.in/ezKhAzkq

Today, Metagenomi announced the appointment of Luis Borges, Ph.D., as Chief Scientific Officer and Pamela Wapnick, MBA, as Chief Financial Officer.

“I am excited to welcome Luis and Pamela to expand the scientific and financial strength of our leadership team,” said Brian C. Thomas, Ph.D., CEO and founder of Metagenomi. “The talent, experience, and in-depth knowledge that Luis and Pamela bring will be instrumental in the execution of our strategy at a time when Metagenomi is rapidly advancing multiple therapeutic programs towards clinical development. I am proud of the world-class team we have assembled, driven by our passion and commitment to develop curative therapeutics for patients using our proprietary, metagenomics-derived genome editing toolbox.”

Read more about this appointment in our latest press release: https://lnkd.in/gvMuCU8h

DNSSEC

Amazon

IPv6

jsDelivr

Cloudflare JS

Google

CDN JS

jQuery CDN

Ruby on Rails Token

Envoy

CEO and Founder

Brian Thomas

Co-Founder, CBO

Jak Knowles

President & COO

Jian Irish

Business Management

Alan Brooks

Senior Vice President

Alan Cohen

Vice President of Biology

Gregory Cost

Vice President Human Resources

Lindsay Caldwell

Vice President Legal

Simren Delaney

DIrector, Process Engineering, Tech-Ops

Anil Chhibbar

Engineering

Ashish Bezawada

Sebastian Bernales

Risa Stack

Santhosh Palani

Jurg Eckhardt

Jillian Banfield

Co-Founder

CEO & Founder

Christine Foster

Chief Business Officer

Simon Harnest

Chief Investment Officer & SVP Strategy

Luis Borges

Chief Scientific Officer

Pamela Wapnick

Chief Financial Officer

Western US Companies With Less Than $10M in Revenue (Top 10K)

West Coast Artificial Intelligence (AI) Female Founded Companies

West Coast Companies With More Than 50 Employees (Top 10K)

Artificial Intelligence (AI) Companies With More Than 10 Employees (Top 10K)

Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world.

The company was founded in 2018 and is headquartered in Emeryville, California.

Series B - Metagenomi

Corporate Round - Metagenomi

PFM Health Sciences

Grant - Metagenomi

Series A - Metagenomi

Bayer

Seed Round - Metagenomi

Emeryville

California

United States

North America

The Gross Law Firm Notifies Metagenomi, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MGX

MGX DEADLINE MONDAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action – MGX

DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024

MGX DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action - MGX

November 25, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MGX

MGX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In MGX To Contact Him Directly To Discuss Their Options

Shareholders that lost money on Metagenomi, Inc. (MGX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

MGX FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action - MGX

A platform that uses artificial intelligence and metagenomics to discover novel genome editing tools from natural environments.

A comprehensive set of genome editing tools including programmable nucleases, base editors, and RNA- and DNA-mediated integration systems for various genetic modifications.

Tools that create targeted genomic breaks to integrate or deactivate genes in a site-specific manner.

Highly efficient genome editing systems that are small enough to be delivered via single AAV for targeting organs.

Tools for making single nucleotide changes, compatible with various delivery technologies.

Systems that use RNA templates to make programmable genomic modifications, including small and large edits.

India

Asia

Senior Director, Analytical Sciences & Quality Control

Head, Analytical Sciences

Director, AAV Process and Analytical Development

Manager

Senior Director, Analytical Sciences & Quality Control at Metagenomi

Kok-Seong Lim

Director Program Management

Contract Project Manager

Senior Project Portfolio Manager

Senior Program Manager

Program Manager

Donella Meadows Sustainability Leadership Fellow

Sr EHS Specialist

Business Analyst

Director Program Management Drug Discovery and Early Development

Tse-Sung Wu

Associate Director, Cell Therapy

Associate Director, Research & Site Head, Century Therapeutics Canada

CoFounder & Director, Preclinical Development

Program Director

Program Scientist

Post Doctoral Fellow

Teaching Assistant

PHD Student

Parvez Vora

Director, Novel Delivery Technologies for Genetic Medicines

Chemistry of LNPs for RNA Delivery  | Target Validation | Treg Cell Therapy

Senior Scientist

Scientist

Center for Systems Biology Research Scientist

Post Doctoral

Cell and Gene Therapy | Immunology | RNA Delivery | Nanoparticles | Chemistry

Carlos Tassa

Associate Director

Senior Researcher

Postdoctoral position

Postdoc

PhD student

Cindy Castelle

Associate Director, Process Development and Validation

Senior Process Engineer, Cell Culture and Purification

Process Engineer, Cell Culture

Cell Culture, Lead Master Associate

Cell Culture, Senior Associate

Cell Culture Associate Scientist

Cell Culture Manufacturing Associate

Internship

Assistant to Director of Engineering and Director of Marketing

Executive Board Director

President/COO

Member of SAB

Member Of SAB

Interim COO

President/COO and Board Director at Metagenomi / Women in Biopharma ‘22 / Biopharma Veteran

news impact assignment basic	general
public peers	general
news daily refresh	general	Sep 1, 2024 11:10 AM	0fb48a2f
news processing daily refresh	general	Aug 30, 2024 4:17 AM	0f7418f5
news impact assignment daily	general	Aug 30, 2024 8:38 AM	08290bdb
news processing basic	general
company summary	general	Aug 30, 2024 12:00 PM	6861fad3
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	02a7ecba
crunchbase profile	general	Nov 27, 2024 1:25 PM	5af65236
li profile	general	Feb 5, 2024 8:46 PM	b73131ca
translate crunchbase fundingrounds	general	Nov 28, 2024 2:25 PM	c76a5886
peers	general	Feb 5, 2024 8:46 PM	03559ce6
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

MGX

CO:METAGENOMI

Metagenomi

Last Close

1.82

22/11 21:00

Market Cap

162.97M

Beta: -

Volume Today

466.92K

Avg: -